Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/08/17Natera Reports Third Quarter 2017 Financial Results
SAN CARLOS, Calif., Nov. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2017 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $56.7 million in the third quarter of 2017 compared to $53.9 million in the third quarter o... 
11/06/17Natera Selected for Circulating Tumor DNA Study in Colorectal Cancer
Second Study with Denmark's Aarhus University to Leverage Signatera™ (RUO) Personalized ctDNA Technology SAN CARLOS, Calif., Nov. 6, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a second research collaboration with Denmark's Aarhus University utilizing the company's Signatera™ (RUO) technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal... 
11/02/17Natera Inc. Announces Third Quarter 2017 Earnings Conference Call
SAN CARLOS, Calif., Nov. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its third quarter ended September 30, 2017 after the market close on November 8, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: Event:  Natera's Third Qu... 
11/01/17Natera Chosen for Longitudinal Circulating Tumor DNA Study in Breast Cancer
Collaboration with Imperial College London and University of Leicester to Leverage Signatera™ (RUO) Personalized ctDNA Technology SAN CARLOS, Calif., Nov. 1, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Imperial College London and the University of Leicester, U.K., to leverage the company's Signatera™ (RUO) personalized circulating tumor DNA (ctDNA) technology to evaluate retrospectively the use o... 
10/02/17Natera's Panorama Non-Invasive Prenatal Test Now Available for Screening Twin Pregnancies
First NIPT to Determine Zygosity for Twins as Early as Nine Weeks' Gestation SAN CARLOS, Calif., Oct. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that the company's Panorama® non-invasive prenatal test (NIPT) is now validated to screen twin pregnancies for zygosity (identical or non-identical/fraternal) and chromosomal abnormalities. Natera's Panora... 
09/20/17Natera Selected for Circulating Tumor DNA Study in Bladder Cancer
Denmark's Aarhus University to Use Signatera™ ctDNA Technology in Longitudinal Study SAN CARLOS, Calif., Sept. 20, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Denmark's Aarhus University to leverage the company's Signatera™ (RUO) personalized liquid biopsy technology to evaluate circulating tumor DNA (ctDNA) as a useful biomarker in the diagnosis and treatment of bladder cancer. Signatera™ was re... 
08/21/17Natera Launches Signatera™ Personalized Circulating Tumor DNA Technology for Cancer Research
SAN CARLOS, Calif., Aug. 21, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the launch of SignateraTM, a circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific to an individual's tumor, for research use only (RUO) by oncology researchers and biopharmaceutical companies. Already in clinical validation with multiple world-leading cancer institutes, SignateraTM offers a no... 
08/08/17Natera Reports Second Quarter 2017 Financial Results
SAN CARLOS, Calif., Aug. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2017 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $53.6 million in the second quarter of 2017 compared to $52.0 million in the second quarter of ... 
08/01/17Natera Inc. Announces Second Quarter 2017 Earnings Conference Call
SAN CARLOS, Calif., Aug. 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its second quarter ended June 30, 2017 after the market close on August 8, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: Event:             ... 
07/31/17Large Study Shows Natera’s Panorama Prenatal Screen To Be Highly Accurate in Identifying DNA Microdeletions Associated with Serious Health Implications
Study evaluated screening performance for 22q11.2, 1p36, Prader-Willi, Angelman, and cri-du-chat microdeletion syndromes Using new testing methodology, positive predictive values improved to 44.2% for 22q11.2 deletion syndrome and 31.7% for four other microdeletion disorders False positive rates decreased to 0.07% for 22q11.2 and 0.07% for the other four disorders combined Prevalence in... 
05/09/17Natera Reports First Quarter 2017 Financial Results
SAN CARLOS, Calif., May 9, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent business progress. Recent Accomplishments & Highlights Processed greater than 121,000 tests, including greater than 114,000 tests accessioned in Natera's laboratory and greater than 6,300 units processed through i... 
05/08/17Natera, Inc. Announces Launch of Vistara Single-Gene Mutation NIPT
A NIPT to screen for single gene disorders using cfDNA SAN CARLOS, Calif., May 8, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in genetic testing, announced the launch of Vistara, a non-invasive prenatal test (NIPT) to screen single-gene disorders. Vistara is a complement to Natera's market-leading Panorama® non-invasive prenatal test (NIPT) and screens for new mutations in 30 genes that have a combined incidence rate of nearly 1 in 600, which is higher than that of Down syndrome.1,... 
05/04/17Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors
Experienced Healthcare Executive Adds Deep Experience in Managed Care and Market Access SAN CARLOS, Calif., May 4, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Gail Marcus as member of the board of directors, effective March 2017. Ms. Marcus has served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International since 2015.... 
05/02/17Natera Inc. Announces First Quarter 2017 Earnings Conference Call
SAN CARLOS, Calif., May 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its first quarter ended March 31, 2017 after the market close on May 9, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.   Conference Call Information: Event:               N... 
04/26/17Study in Nature Shows Early Relapse Detection in Lung Cancer Using Natera's Technology for ctDNA Analysis
Relapse detected up to 347 days earlier than standard of care, with sensitivity and specificity exceeding 90% SAN CARLOS, Calif. and LONDON, April 26, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, and Cancer Research UK, University College of London (UCL) Cancer Institute and the Francis Crick Institute today announced the publication of results from the first 100 patients in the Cancer Research UK-funded TRACERx study (Tracking Cancer Evolutio... 
03/07/17Natera Reports Fourth Quarter and Fiscal Year 2016 Financial Results
SAN CARLOS, Calif., March 7, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $49.3 million in the fourth quarter of 2016 compared to $52.9 million... 
03/01/17Natera, Inc. Announces Launch of Evercord™ Cord Blood and Tissue Banking Service
Launch Expands Natera's Leadership Position in Women's Reproductive Health SAN CARLOS, Calif., March 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in genetic testing, today announced the upcoming launch of Evercord; a new offering being made commercially available in the second quarter of 2017 that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. ... 
02/28/17Natera Inc. Announces Fourth Quarter and Fiscal Year 2016 Earnings Conference Call
SAN CARLOS, Calif., Feb. 28, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2016 after the market close on March 7, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Confe... 
02/03/17Natera Inc. Announces Appointment of Mike Brophy as New Chief Financial Officer
Former Chief Financial Officer Herm Rosenman to Join Natera's Board of Directors SAN CARLOS, Calif., Feb. 3, 2017 /PRNewswire/ -- Natera Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Mike Brophy as Natera's new chief financial officer, effective February 1, 2017. Mr. Brophy replaces Herman ("Herm") Rosenman, who joined the Company's board of directors effective February 1, 2017 following his three-year tenure as Natera's current CFO, a pos... 
01/17/17Natera Announces Results From DNAFirst Study, Validating Use Of NIPT In Routine Prenatal Care
Results demonstrate clinical utility of NIPT as first line screen in a general population Study results published in Genetics in Medicine SAN CARLOS, Calif., Jan. 17, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the results from the DNAFirst trial, showing that non-invasive prenatal screening tests (NIPT) can be effectively and appropriately offered as a primary screen for all pregnant women, regardless of risk due to matern... 
01/10/17Natera Inc. Terminates NIPT Distribution Agreement with Bioreference Labs
SAN CARLOS, Calif., Jan. 10, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced the termination of a distribution agreement with Bioreference Laboratories. With the ending of the distribution agreement, Natera intends to promote Panorama directly to clinicians, who previously ordered this test through Bio-Reference. Natera also plans to promote its Horizon carrier screen test to these clinicians, which it had not done previously. ... 
Shareholder Tools